These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15230149)

  • 1. [Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia].
    Rajzer M; Wojciechowska W; Kawecka-Jaszcz K
    Przegl Lek; 2004; 61(2):94-8. PubMed ID: 15230149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z; Placha G
    J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacotherapy for weight loss in patients with type 2 diabetes].
    Toubro S
    Ugeskr Laeger; 2007 Aug; 169(33):2619-22. PubMed ID: 17725907
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
    Maggioni AP; Caterson I; Coutinho W; Finer N; Gaal LV; Sharma AM; Torp-Pedersen C; Bacher P; Shepherd G; Sun R; James P;
    J Cardiovasc Pharmacol; 2008 Nov; 52(5):393-402. PubMed ID: 19033818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current pharmacological approaches to the treatment of obesity.
    Hauner H
    Int J Obes Relat Metab Disord; 2001 May; 25 Suppl 1():S102-6. PubMed ID: 11466601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Weight reduction. Antiobesity drug treatment in type-2 diabetics].
    Verspohl EJ
    Pharm Unserer Zeit; 2002; 31(3):300-7. PubMed ID: 12071127
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes.
    Hung YJ; Chen YC; Pei D; Kuo SW; Hsieh CH; Wu LY; He CT; Lee CH; Fan SC; Sheu WH
    Diabet Med; 2005 Aug; 22(8):1024-30. PubMed ID: 16026368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sibutramine-associated adverse effects: a practical guide for its safe use.
    Florentin M; Liberopoulos EN; Elisaf MS
    Obes Rev; 2008 Jul; 9(4):378-87. PubMed ID: 18034790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Croatian experience with sibutramine in the treatment of obesity--multicenter prospective study.
    Stimac D; Ruzić A; Majanović SK
    Coll Antropol; 2004 Jun; 28(1):215-21. PubMed ID: 15636078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
    Kiortsis DN; Tsouli S; Filippatos TD; Konitsiotis S; Elisaf MS
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):207-10. PubMed ID: 17570651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evidence for drug treatments in obesity-associated hypertensive patients--a discussion paper.
    Doggrell SA
    Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):119-25. PubMed ID: 15834464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sibutramin in obesity treatment (multicenter, open, prospective 12-month-long study)].
    Payer J; Hainer V; Ondrejka P; Kajtor Z
    Vnitr Lek; 2004 Nov; 50(11):825-9. PubMed ID: 15648961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Wang TF; Pei D; Li JC; Tsai WC; Tsai CC; Yao CY; Chang ET; Hsieh MC; Su KY; Kuo SW
    Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.